BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

881

500124

DRREDDY

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

DR. REDDY S LABORATORIES performance

Today’s low

Today’s high

₹ 1175.90 ₹ 1196.60
₹ 1183.90

52 week low

52 week high

₹ 1020.00 ₹ 1421.49
₹ 1183.90

Open Price

₹ 1176.20

Prev. Close

₹ 1176.00

Volume (Shares)

1604442.00

Total traded value

₹ 18994.98

Upper Circuit

₹ 1293.60

Lower Circuit

₹ 1058.40

info

DR. REDDY S LABORATORIES Share Price Update

As of the latest trading session, DR. REDDY S LABORATORIES share price is currently at ₹ 1183.9, which is up by ₹ 7.90 from its previous closing. Today, the stock has fluctuated between ₹ 1175.90 and ₹ 1196.60. Over the past year, DR. REDDY S LABORATORIES has achieved a return of -4.59 %. In the last month alone, the return has been 2.75 %. Read More...

DR. REDDY S LABORATORIES fundamentals


  • Market cap (Cr)

    19,749.62

  • P/E Ratio (TTM)

    19.04

  • Beta

    0.54

  • Book Value / share

    322.46

  • Return on equity

    19.42%

  • EPS (TTM)

    62.12

  • Dividend yield

    0.68%

  • Net profit/quarter (Cr)

    849.40

info icon alternate text
  • Market cap (Cr)

    19,734.60

  • P/E Ratio (TTM)

    19.04

  • Beta

    0.50

  • Book Value / share

    322.46

  • Return on equity

    19.42%

  • EPS (TTM)

    62.12

  • Dividend yield

    0.68%

  • Net profit/quarter (Cr)

    849.40

info icon alternate text

DR. REDDY S LABORATORIES Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 4997.80
Operating Expense 4131.00
Net Profit 849.40
Net Profit Margin (%) 16.99
Earnings Per Share (EPS) 10.20
EBITDA 1427.80
Effective Tax Rate (%) 24.12
Particulars SEP 2024 (Values in Cr)
Revenue 6678.80
Operating Expense 4263.09
Net Profit 1882.10
Net Profit Margin (%) 28.18
Earnings Per Share (EPS) 113.00
EBITDA 2929.20
Effective Tax Rate (%) 28.72
Particulars JUN 2024 (Values in Cr)
Revenue 5823.90
Operating Expense 4145.10
Net Profit 1417.20
Net Profit Margin (%) 24.33
Earnings Per Share (EPS) 85.10
EBITDA 2170.80
Effective Tax Rate (%) 25.95
Particulars MAR 2024 (Values in Cr)
Revenue 5081.80
Operating Expense 3978.30
Net Profit 1034.80
Net Profit Margin (%) 20.36
Earnings Per Share (EPS) 62.14
EBITDA 1591.30
Effective Tax Rate (%) 22.72
Particulars DEC 2023 (Values in Cr)
Revenue 4083.10
Operating Expense 3698.70
Net Profit 475.20
Net Profit Margin (%) 11.63
Earnings Per Share (EPS) 28.55
EBITDA 883.90
Effective Tax Rate (%) 24.79
Particulars MAR 2024 (Values in Cr)
Revenue 19404.10
Operating Expense 14554.80
Net Profit 4342.00
Net Profit Margin (%) 22.37
Earnings Per Share (EPS) 260.95
EBITDA 6788.70
Effective Tax Rate (%) 25.02
Particulars MAR 2023 (Values in Cr)
Revenue 16899.10
Operating Expense 13687.80
Net Profit 2612.80
Net Profit Margin (%) 15.46
Earnings Per Share (EPS) 157.37
EBITDA 4806.10
Effective Tax Rate (%) 32.41
Particulars MAR 2022 (Values in Cr)
Revenue 14315.30
Operating Expense 12663.40
Net Profit 1623.20
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 97.85
EBITDA 3076.10
Effective Tax Rate (%) 27.00
Particulars MAR 2021 (Values in Cr)
Revenue 13281.40
Operating Expense 11094.00
Net Profit 2186.40
Net Profit Margin (%) 16.46
Earnings Per Share (EPS) 131.84
EBITDA 3937.89
Effective Tax Rate (%) 28.46
Particulars MAR 2020 (Values in Cr)
Revenue 11803.00
Operating Expense 9817.80
Net Profit 2937.70
Net Profit Margin (%) 24.88
Earnings Per Share (EPS) 177.23
EBITDA 3612.80
Effective Tax Rate (%) -5.83
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1699.87
ROE % 21.64
ROCE % 26.59
Total Debt to Total Equity 0.06
EBITDA Margin 31.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1405.34
ROE % 21.21
ROCE % 25.99
Total Debt to Total Equity 0.11
EBITDA Margin 30.16
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1164.21
ROE % 11.84
ROCE % 14.46
Total Debt to Total Equity 0.17
EBITDA Margin 20.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1072.02
ROE % 11.74
ROCE % 15.29
Total Debt to Total Equity 0.16
EBITDA Margin 22.10
Particulars MAR 2020 (Values in Cr)
Book Value / Share 944.61
ROE % 13.68
ROCE % 10.95
Total Debt to Total Equity 0.20
EBITDA Margin 17.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1459.23
ROE % 19.42
ROCE % 25.40
Total Debt to Total Equity 0.02
EBITDA Margin 34.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1236.56
ROE % 13.46
ROCE % 18.82
Total Debt to Total Equity 0.06
EBITDA Margin 28.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1111.56
ROE % 9.19
ROCE % 11.63
Total Debt to Total Equity 0.10
EBITDA Margin 21.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1032.48
ROE % 11.50
ROCE % 15.04
Total Debt to Total Equity 0.08
EBITDA Margin 25.97
Particulars MAR 2020 (Values in Cr)
Book Value / Share 920.13
ROE % 21.08
ROCE % 18.48
Total Debt to Total Equity 0.09
EBITDA Margin 30.49
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1727.70
Total Assets 38863.80
Total Liabilities 38863.80
Total Equity 28254.80
Share Outstanding 166818266
Price to Book Ratio 4.22
Return on Assets (%) 14.35
Return on Capital (%) 18.65
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1730.20
Total Assets 32285.10
Total Liabilities 32285.10
Total Equity 23286.10
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 13.96
Return on Capital (%) 18.47
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2419.20
Total Assets 29746.90
Total Liabilities 29746.90
Total Equity 19212.40
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 7.33
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2078.80
Total Assets 26616.80
Total Liabilities 26616.80
Total Equity 17641.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 7.33
Return on Capital (%) 9.6
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 205.30
Total Assets 23225.30
Total Liabilities 23225.30
Total Equity 15598.80
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 8.72
Return on Capital (%) 11.66
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1216.90
Total Assets 30359.30
Total Liabilities 30359.30
Total Equity 24240.80
Share Outstanding 166818466
Price to Book Ratio 4.22
Return on Assets (%) 14.30
Return on Capital (%) 17.4
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 645.80
Total Assets 25374.80
Total Liabilities 25374.80
Total Equity 20474.20
Share Outstanding 166527876
Price to Book Ratio 3.74
Return on Assets (%) 10.29
Return on Capital (%) 12.76
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2030.50
Total Assets 24495.60
Total Liabilities 24495.60
Total Equity 18336.20
Share Outstanding 166426049
Price to Book Ratio 3.87
Return on Assets (%) 6.62
Return on Capital (%) 7.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1646.50
Total Assets 21629.60
Total Liabilities 21629.60
Total Equity 16983.70
Share Outstanding 166301431
Price to Book Ratio 4.37
Return on Assets (%) 10.10
Return on Capital (%) 12.04
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 39.20
Total Assets 19475.80
Total Liabilities 19475.80
Total Equity 15191.90
Share Outstanding 166172082
Price to Book Ratio 3.39
Return on Assets (%) 15.08
Return on Capital (%) 18.07
Particulars MAR 2024 (Values in Cr)
Net Income 7201.00
Cash from Operations 6548.00
Cash from Investing -4028.30
Cash from Financing -376.30
Net change in Cash 138.70
Free Cash Flow 8188.30
Particulars MAR 2023 (Values in Cr)
Net Income 6048.50
Cash from Operations 6958.90
Cash from Investing -4137.30
Cash from Financing -2686.10
Net change in Cash -935.90
Free Cash Flow 8091.20
Particulars MAR 2022 (Values in Cr)
Net Income 3061.40
Cash from Operations 3554.50
Cash from Investing -2638.70
Cash from Financing -242.20
Net change in Cash -70.10
Free Cash Flow 5020.50
Particulars MAR 2021 (Values in Cr)
Net Income 2883.50
Cash from Operations 4141.90
Cash from Investing -2266.00
Cash from Financing -29.80
Net change in Cash 1274.50
Free Cash Flow 5116.00
Particulars MAR 2020 (Values in Cr)
Net Income 1885.70
Cash from Operations 3694.60
Cash from Investing -492.30
Cash from Financing -2515.90
Net change in Cash -24.10
Free Cash Flow 4179.20
Particulars MAR 2024 (Values in Cr)
Net Income 5791.30
Cash from Operations 4769.20
Cash from Investing -3430.30
Cash from Financing 68.10
Net change in Cash 87.50
Free Cash Flow 6130.29
Particulars MAR 2023 (Values in Cr)
Net Income 3866.00
Cash from Operations 5835.60
Cash from Investing -3447.60
Cash from Financing -2696.90
Net change in Cash -1091.60
Free Cash Flow 6835.80
Particulars MAR 2022 (Values in Cr)
Net Income 2223.80
Cash from Operations 1827.50
Cash from Investing -2038.00
Cash from Financing 505.50
Net change in Cash -193.80
Free Cash Flow 3138.80
Particulars MAR 2021 (Values in Cr)
Net Income 3056.20
Cash from Operations 3962.20
Cash from Investing -1458.00
Cash from Financing -794.30
Net change in Cash 1261.90
Free Cash Flow 4819.70
Particulars MAR 2020 (Values in Cr)
Net Income 2775.80
Cash from Operations 2316.10
Cash from Investing -1689.20
Cash from Financing -224.10
Net change in Cash -74.10
Free Cash Flow 2742.29
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

DR. REDDY S LABORATORIES Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1183.90 0.67 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 1182.70
  • 26 Days 1163.90
  • 10 Days 1175.40
  • 50 Days 1172.70
  • 12 Days 1172.60
  • 100 Days 1202.20
  • 20 Days 1165.60
  • 200 Days 1224.30
1183.13 PIVOT

First Support

1161.87

First Resistance

1197.27

Second Support

1147.73

Second Resistance

1218.53

Third Support

1126.47

Third Resistance

1232.67

RSI

54.99

ADX

8.29

MACD

8.67

Williams % R

-17.87

Commodity Channel Index (CCI)

77.60

Date

2025-04-30

Week

1344981.00

Same Day

939467.00

Month

1724696.00

1 Year

0.54

3 Year

0.50

Over 1 Month

2.75%

down

Over 1 Year

-4.59%

down

Over 3 Months

-0.88%

down

Over 3 Years

12.80%

down

Over 6 Months

-5.27%

down

Over 5 Years

8.50%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

DR. REDDY S LABORATORIES shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
10.44%
Promoter Holdings
26.64%
FII
37.29%
DII
25.61%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
J P Morgan Chase Bank Na 9.6312429E7 (11.54%) Public Shareholding
G V Prasad 9.609592E7 (11.52%) Shareholding of Promoter and Promoter Group
Satish Reddy Kallam 8.5738125E7 (10.27%) Shareholding of Promoter and Promoter Group
Life Insurance Corporation Of India P & Gs Fund 6.0015393E7 (7.19%) Public Shareholding
Icici Prudential Value Discovery Fund 3.1659572E7 (3.79%) Public Shareholding
Kallam Satish Reddy Huf 2.7618385E7 (3.31%) Shareholding of Promoter and Promoter Group
Nps Trust-a/c Sbi Pension Fund Scheme Tax Saver-tier 2 2.042371E7 (2.45%) Public Shareholding
Nippon Life India Trustee Ltd-a/c-nippon India Nifty 50 Value 20 Index Fund 1.6247593E7 (1.95%) Public Shareholding
Gunupati Venkateswara Prasad Huf 1.271709E7 (1.52%) Shareholding of Promoter and Promoter Group
First Sentier Investors Icvc - Stewart Investors Asia Pacific Leaders Sustainability Fund 1.2106171E7 (1.45%) Public Shareholding
Sbi Nifty Index Fund 1.1411189E7 (1.37%) Public Shareholding
Parag Parikh Flexi Cap Fund 1.0653386E7 (1.28%) Public Shareholding
Anuradha Gunupati 46025.0 (0.01%) Shareholding of Promoter and Promoter Group
Sharathchandra Reddy Gunupati 13000.0 (0.0%) Shareholding of Promoter and Promoter Group
Aps Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vsd Holdings & Advisory Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
K Vishal Reddy 0.0 (0.0%) Shareholding of Promoter and Promoter Group
K Shravya Reddy 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Gunupati Mallika Reddy 25695.0 (0.0%) Shareholding of Promoter and Promoter Group
G Vani Sanjana Reddy 25700.0 (0.0%) Shareholding of Promoter and Promoter Group
Deepti Reddy Kallam 25700.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

DR. REDDY S LABORATORIES corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Jul 2023 40.0 Final 12 Jul 2023 Equity shares
11 Jul 2022 30.0 Final 13 Jul 2022 Equity shares
09 Jul 2021 25.0 Final 13 Jul 2021 Equity shares
13 Jul 2020 25.0 Final 15 Jul 2020 Equity shares
15 Jul 2019 20.0 Final 17 Jul 2019 Equity shares
16 Jul 2018 20.0 Final 18 Jul 2018 Equity shares
17 Jul 2017 20.0 Final 19 Jul 2017 Equity shares
18 Jul 2016 20.0 Final 20 Jul 2016 Equity shares
10 Jul 2015 20.0 Final 14 Jul 2015 Equity shares
11 Jul 2014 18.0 Final 15 Jul 2014 Equity shares
12 Jul 2013 15.0 Final 16 Jul 2013 Equity shares
28 Jun 2012 13.75 Final 03 Jul 2012 Equity shares
30 Jun 2011 11.25 Final 05 Jul 2011 Equity shares
02 Jul 2010 11.25 Final 06 Jul 2010 Equity shares
03 Jul 2009 6.25 Final 07 Jul 2009 Equity shares
04 Jul 2008 3.75 Final 08 Jul 2008 Equity shares
06 Jul 2007 3.75 Final 10 Jul 2007 Equity shares
07 Jul 2006 0.0 Final 11 Jul 2006 Equity shares
07 Jul 2005 0.0 Final 11 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
29 Aug 2006 28 Aug 2006 1:1
03 May 1994 08 Apr 1994 2:1
Ex-Date Old FV NEW FV Record Date
10 Oct 2001 10.0 5.0 25 Oct 2001
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
11 Jul 2023 40.0 Final 12 Jul 2023 Equity shares
11 Jul 2022 30.0 Final 13 Jul 2022 Equity shares
09 Jul 2021 25.0 Final 13 Jul 2021 Equity shares
13 Jul 2020 25.0 Final 15 Jul 2020 Equity shares
15 Jul 2019 20.0 Final 17 Jul 2019 Equity shares
16 Jul 2018 20.0 Final 18 Jul 2018 Equity shares
17 Jul 2017 20.0 Final 19 Jul 2017 Equity shares
18 Jul 2016 20.0 Final 20 Jul 2016 Equity shares
10 Jul 2015 20.0 Final 14 Jul 2015 Equity shares
11 Jul 2014 18.0 Final 15 Jul 2014 Equity shares
12 Jul 2013 15.0 Final 16 Jul 2013 Equity shares
28 Jun 2012 13.75 Final 03 Jul 2012 Equity shares
30 Jun 2011 11.25 Final 05 Jul 2011 Equity shares
02 Jul 2010 11.25 Final 06 Jul 2010 Equity shares
03 Jul 2009 6.25 Final 07 Jul 2009 Equity shares
04 Jul 2008 3.75 Final 08 Jul 2008 Equity shares
06 Jul 2007 3.75 Final 10 Jul 2007 Equity shares
07 Jul 2006 0.0 Final 11 Jul 2006 Equity shares
07 Jul 2005 0.0 Final 11 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
29 Aug 2006 28 Aug 2006 1:1
03 May 1994 08 Apr 1994 2:1
Ex-Date Old FV NEW FV Record Date
10 Oct 2001 10.0 5.0 25 Oct 2001

Dr Reddy's Laboratories Limited Overview

Dr. Reddy's Laboratories Ltd, an eminent pharmaceutical company based in India, offers an extensive portfolio across Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Dominating its revenue, the Global Generics Segment, constituting about 83% in FY22, includes over 400 generic drugs with significant contributions from nervous system, gastrointestinal, and anti-infective drugs. The Pharmaceutical Services & Active Ingredients (PSAI) segment, accounting for 14% of revenues, underscores its position as one of the world's largest API manufacturers, benefiting its generics business with cost competitiveness. Meanwhile, its proprietary products focus on differentiated formulations, with subsidiary Aurgene Discovery advancing novel therapeutics for cancer and inflammation. Geographically, the USA leads its revenue share at 37%, followed by India and Russia. The company boasts 23 manufacturing facilities worldwide and maintains a strategic focus on niche products, injectables, and biosimilars to enhance profitability. FY21 saw partnerships for COVID-19 treatments, including the launch of the Sputnik-V vaccine in India. Recent divestments and acquisitions, such as the portfolio from Eton Pharmaceuticals, reflect its commitment to streamlining operations and expanding its product offerings, supporting its mission to provide affordable medications globally.

Dr Reddy Share Result Highlights

Metric

Value

Share Price (NSE)

₹1272.05 (as of 12 Nov 2024)

Market Cap

₹21,220.12 Cr (Q3 2024)

Day Range

₹1269.20 - ₹1288.40 (12 Nov 2024)

52-Week Range

₹1074.00 - ₹1421.49 (2023-2024)

Volume (Shares)

2,86,546 (12 Nov 2024)

PE Ratio (TTM)

22.35 (Q3 2024)

Earnings Per Share (EPS)

₹113.00 (Q3 2024)

Dividend Yield

0.62% (Q3 2024)

Net Profit Margin

28.18% (Q3 2024)

Effective Tax Rate

28.72% (Q3 2024)

Key Highlights

  • Dr Reddy share price currently stands at ₹1272.05 as of 12 Nov 2024, reflecting recent trading data.

  • Market Cap for Dr Reddy's reached ₹21,220.12 Cr in Q3 2024, emphasising its market strength.

  • Trading Volume shows high activity with 2,86,546 shares traded on 12 Nov 2024.

  • EPS for Dr Reddy's is ₹113.00 in Q3 2024, indicating solid earnings.

  • Dividend Yield for Dr Reddy shares recorded at 0.62% in Q3 2024, offering attractive shareholder returns.

Dr Reddy Share Annual Reports

Metric

Value

Annual Revenue

₹6678.80 Cr (Sep 2024)

Net Profit

₹1882.10 Cr (Sep 2024)

Operating Expense

₹4263.09 Cr (Sep 2024)

EBITDA

₹2929.20 Cr (Sep 2024)

Net Profit Margin

28.18% (Sep 2024)

Return on Equity (ROE)

19.42% (Q3 2024)

Book Value per Share

₹322.48 (Q3 2024)

Key Highlights

  • Dr Reddy share price is influenced by strong annual revenue, reaching ₹6678.80 Cr as of Sep 2024.

  • Net Profit stands at ₹1882.10 Cr (Sep 2024), underscoring profitability.

  • Operating Expense recorded at ₹4263.09 Cr for Sep 2024, highlighting operational control.

  • EBITDA of ₹2929.20 Cr (Sep 2024) reflects robust earnings before tax.

  • Indicators from this performance may impact Dr Reddy future share price, as market outlook is often shaped by financial stability.

Dr Reddy Share Dividend

Dividend Type

Dividend Amount

Ex-Date

Record Date

Final

₹40 per share

11 Jul 2023

12 Jul 2023

Final

₹30 per share

11 Jul 2022

13 Jul 2022

Final

₹25 per share

09 Jul 2021

13 Jul 2021

Final

₹25 per share

13 Jul 2020

15 Jul 2020

Final

₹20 per share

15 Jul 2019

17 Jul 2019

Final

₹20 per share

16 Jul 2018

18 Jul 2018

Key Highlights

  • Dr Reddy share price reflects consistent returns with regular dividends, enhancing investor confidence.

  • The most recent dividend was ₹40 per share with an ex-date of 11 Jul 2023.

  • Dr Reddy's long-term dividend history showcases its commitment to rewarding shareholders.
     

DR. REDDY S LABORATORIES Share Price

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include - USA, India, Russia & CIS countries, and Europe.

Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh. It was founded to enable patients to access life-saving medicines and to use science and innovations to
open new avenues to meet unmet medical needs. The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad, India. In the year 1986, the company shares were listed on the Bombay Stock Exchange. Also, they entered international market with exports of Methyldopa.

In the year 1987, the company obtained first USFDA approval for Ibuprofen API. In the year 1988, they acquired Benzex Laboratories Pvt Ltd to expand their Bulk Actives business. In the year 1990, they exported Norfloxacin and Ciprofloxacin to Europe and Far East. In the year 1991, they commenced formulation exports to Russia.

In the year 1993, the company established Dr. Reddy's Research Foundation and initiated drug discovery programme. In the year 1994, they finished dosages facility established to cater to highly regulated markets such as the US. In the year 1995, the company set up joint venture in Russia. In the year 1997, they filled first ANDA with the United States Food and Drug Administration for Ranitidine.

In the year 1999, the company acquired American Remedies Ltd, a pharmaceutical company based in India. In the year 2000, Cheminor Drugs Ltd, a group company merged with the company and thus the company became India's third largest pharma company. In the year 2001, the company launched Fluoxetine capsules. They became the first Indian company to win 180-day exclusivity for a generic drug in the US. Also, they launched their first generic product, Ranitidine, in the US market.

In the year 2002, the company made their first overseas acquisition of BMS Laboratories Limited and Meridian Healthcare in UK. In the year 2003, they launched Ibuprofen, first generic product to be marketed under the 'Dr. Reddy's' label in the US. In the year 2005, they acquired Roche's API Business at its manufacturing site in Mexico.

In the year 2006, the company acquired Betapharm the fourth largest generics company in Germany for a total enterprise value of Rs 480 million. In the year 2007, the company launched Reditux - the world's first biosimilar MAb - for the treatment of Non Hodgkins Lymphoma. Also, they became India's leading and most profitable pharmaceutical company.

During the year 2008-09, the company acquired DowPharma's small molecules business in UK under Chirotech Technology Ltd, BASF Corporation's manufacturing facility at Shreveport in Louisiana, USA under Dr. Reddy's Laboratories Louisiana LLC and Jet Generici SRL, a company engaged in the sale of generic finished dosages in Italy. In addition, Perlecan Pharma Pvt Ltd, Macred India Pvt Ltd and Dr. Reddy's Laboratories ILAC Ticaret also became subsidiary of the company.

During the year 2009-10, Dr. Reddy's Pharma SEZ Ltd was incorporated as a wholly-owned subsidiary of the company for the purpose of formulation manufacturing at Special Economic Zone and Perlecan Pharma Pvt Ltd was amalgamated with the company. Further, the company acquired the balance stake of 30% in Dr. Reddy's (Australia) Pty Ltd. The company filed 12 Abbreviated New Drug Applications (ANDAs) in US including six Para IV filing during the year.

During the year 2010-11, the company acquired GlaxoSmithKline's (GSK) oral penicillin manufacturing facility located in Tennessee, USA. This allows the company to enter theUS penicillin-containing antibacterial market segment through brands such as Augmentin and Amoxil, and serve the needs of customers through manufacturing and other capabilities that did not previously exist within the company. Also, they increased the stake in the South African joint venture company to 100% after acquiring the 40% stake of the partner.

During the year, the company launched Cresp in India, the first biosimilar darbepoetin alfa in the world. In March 2011, they launched Peg-grafeelTM in India in the form of an affordable pegfilgrastim, which is used to stimulate the bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy. Peg-grafeelTM

During the year, Idea2Enterprises (India) Pvt Ltd, Dr. Reddy's Laboratories Romania SRL, I-Ven Pharma Capital Ltd, Dr. Reddy's Laboratories Tennessee LLC and Dr. Reddy's Venezuela C.A. became wholly-owned subsidiaries of the company. Further, Dr. Reddy's Laboratories (Proprietary) Ltd also became wholly-owned subsidiary by virtue of purchase of its balance 40% stake by the company. Also, Macred India Pvt Ltd ceased to be a subsidiary of the company.On 27 July 2012, Dr. Reddy's Laboratories announced that the United States Food and Drug Administration (USFDA) had lifted import alert on its chemical manufacturing facility at Cuernavaca, Mexico after inspection of the unit in March 2012. Earlier, Dr. Reddy's Mexico facility was inspected by USFDA in November 2010 and based on observations by the USFDA, a warning letter was issued to the company on 14 June 2011.On 8 October 2012, the Custom Pharmaceutical Services (CPS) business of Dr. Reddy's Laboratories Ltd. announced expansion in the areas of activated mPEG manufacturing and in the development and manufacture of NCE (New Chemical Entities) APIs for use in pre-clinical through to commercial development at its manufacturing facility in Mirfield, UK.On 14 December 2012, Dr. Reddy's Laboratories announced that it had launched the recommended public offer to acquire all the issued and outstanding shares of OctoPlus N.V., a service based specialty pharmaceutical company, at an offer price of EUR 0.52 (cum dividend) per share. Shareholders (including certain members of the Boards) holding in aggregate 63.5% of the issued and outstanding ordinary shares of OctoPlus entered into irrevocable undertakings to tender their shares under the offer. On 28 February 2013, Dr. Reddy's Laboratories announced that it had raised its stake in OctoPlus N.V, to 98.6% following a public offer for all the issued and outstanding ordinary shares in the capital of OctoPlus. OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to formulate active pharmaceutical ingredients.On 19 December 2014, Dr. Reddy's Laboratories announced that it had completed the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. following issuance of the proposed consent order from the US Federal Trade Commission (FTC) on 26 November 2014. The company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights of Habitrol brand and to market the product in the US market.On 22 March 2015, Dr. Reddy's Laboratories (NYSE: RDY) announced that it had settled its claims against Nordion Inc. (formerly MDS Inc.), headquartered in Ottawa, Canada, in a case pending in the United States District Court for the District of New Jersey, for a cash payment of USD 22.5 Million by Nordion to Dr. Reddy's. The case was brought by Dr. Reddy's in April 2009 seeking damages sustained by the company caused by a claimed breach by Nordion of its Laboratory Services Agreement with Dr. Reddy's. Nordion, as a contract research organization, provided laboratory services to Dr. Reddy's, including bio-equivalency studies, to support Dr. Reddy's regulatory applications for approval of generic drugs, including Abbreviated New Drug Applications (ANDAs) filed with the United States Food and Drug Administration (the USFDA) for approval to market generic drugs in the United States. The case arose after the USFDA cited MDS with violations of good laboratory practices which caused the USFDA not to accept, without further substantiation, MDS's laboratory reports performed during the period 2000-2004.

On 23 March 2015, Dr Reddy's Laboratories announced that it has entered into an agreement with Hetero, under which Dr. Reddy's has been licensed to distribute and market Sofosbuvir 400 mg tablets , indicated in the treatment of Chronic Hepatitis C, under the brand name Resof, in India.

On 1 April 2015, Dr. Reddy's Laboratories announced that it has entered into a definitive agreement to acquire a select portfolio of the established products business of UCB, a global biopharmaceutical company, in the territories of India, Nepal, Sri Lanka and Maldives. The revenue of the acquired business stood at approximately Rs 150 crore for calendar year 2014.On 29 May 2015, Dr Reddy's Laboratories Limited and AstraZeneca Pharma India Limited entered into a distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 DiabetesOn 6 August 2015, Dr. Reddy's Laboratories Ltd. announced that it has entered into a strategic collaboration with Amgen, one of the world's leading independent biotechnology companies, to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. On 16 September 2016, Dr. Reddy's announced that it had expanded its strategic collaboration with Amgen to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis.

On 9 September 2015, PanTheryx Inc., a global medical nutrition company based in Boulder, Colorado, and Dr. Reddy's Laboratories Ltd. announced a multi-country supply and licensing agreement whereby Dr. Reddy's Lab got the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention, DiaResQ, for infectious diarrhea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets. Dr. Reddy's will market the product in India and Nepal under the Reliqua brand.

On 14 September 2015, Dr. Reddy's Laboratories announced the signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze Lotion. The exclusive rights for this product are applicable for the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.

On 4 November 2015, Dr. Reddy's Laboratories entered into a strategic alliance with Biocodex, a multinational pharmaceutical company, to market and distribute Biocodex products in the Romanian market.

On 5 November 2015, the US Food and Drug Administration (USFDA) issued a warning letter to Dr. Reddy's Laboratories relating to its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. This action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015 respectively.

On 18 November 2015, Dr. Reddy's Laboratories announced that it had completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic anti-coagulant drug from its Australian partner, Alchemia Limited. Earlier, the company had signed a term sheet for this transaction in September 2015. Fondaparinux is a generic version of the anticoagulant drug Arixtra.

On 11 March 2016, Dr. Reddy's Laboratories Ltd. and TR-Pharm announced a strategic collaboration agreement for the manufacture and commercialization of a portfolio of Dr. Reddy's Laboratories' biosimilar drugs in Turkey.

On 28 March 2016, Dr. Reddy's Laboratories and XenoPort, Inc. announced that they have entered into a license agreement pursuant to which Dr. Reddy's Laboratories will be granted exclusive US rights for the development and commercialization of XenoPort's clinical stage oral new chemical entity, XP23829. Dr. Reddy's Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis and may potentially develop XP23829 for relapsing forms of multiple sclerosis (MS).

On 31 March 2016, Dr. Reddy's Laboratories announced that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddy's holds the option for rights to develop and market the agent in India.

On 25 May 2016, Dr. Reddy's Laboratories announced the acquisition of an eminent portfolio of over-the-counter (OTC) brands in the US in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.

On 3 August 2016, Dr. Reddy's Laboratories announced that it successfully completed the previously announced acquisition of a portfolio of complex generic products in the US from Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc. On 11 June 2016, Dr. Reddy's Laboratories entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc to acquire a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US for $350 million in cash.

On 7 October 2016, Dr. Reddy's Laboratories announced its entry into Colombia with its portfolio of high quality and affordable medicines for Cancer patients.

On 26 October 2016, Dr. Reddy's Laboratories announced that it had entered into a strategic collaboration with Gland Pharma, a globally recognized developer and manufacturer of sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs) in the United States.

On 8 February 2017, Dr. Reddy's Laboratories Ltd announced the expansion of its commercial operations in Europe with the introduction of its portfolio of generics in France.

On 3 March 2017, Dr. Reddy's Laboratories announced that it had completed the acquisition of 100% stake in Imperial Credit Private Limited, a Non-Banking Finance Company (NBFC), based out of Kolkata, for a consideration of Rs 2.05 crore. The company proposes to undertake the group's captive financial activities through this entity.

On 27 March 2017, Dr. Reddy's Laboratories and Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that they have entered into an exclusive distribution agreement. Under the agreement, Dr. Reddy's will market and distribute DuraGen Plus and Suturable DuraGen Dural Regeneration Matrices for use in patients in India. The DuraGen product line offers Duraplasty Solutions meant for the repair of the dura mater. Dura mater is a thick membrane that surrounds the brain and spinal cord, and contains the cerebrospinal fluid (CSF). DuraGen Plus Dural Regeneration Matrix is indicated as a dural substitute for the repair of dura mater.

On 27 July 2017, Dr Reddy's Laboratories Ltd. and CHD Bioscience Inc., a privately-held biopharmaceutical company, announced a global licensing agreement for the clinical development and commercialization of Dr. Reddy's phase III clinical trial candidate, DFA-02. It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Under the terms of the agreement, Dr. Reddy's would receive equity in CHD valued at $30 million upon an IPO of CHD or a minimum of $30 million in cash within 18 months of execution of the agreement. Dr. Reddy's will also receive additional milestone payments of $40 million upon USFDA approval. In addition, CHD will pay Dr. Reddy's double-digit royalties on sales and commercial milestones.

On 22 August 2017, Dr. Reddy's Laboratories Ltd. through its wholly owned subsidiary Promius Pharma, LLC, announced that it has out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology Inc. The drug is intended to be used for treatment of moderate to severe plaque psoriasis. Under the terms of the agreement, Encore will be responsible for the commercialization of DFD-06 in the United States. Promius Pharma is eligible to receive certain pre- and post- commercialization milestone payments of up to USD $32.5 million, followed by fixed royalty payments on net sales.

On 19 December 2017, Dr. Reddy's Laboratories Ltd. announced that its US subsidiary had reached a settlement with the US Government in a case involving packaging for five blister-packed prescription products. In a joint filing by the parties, Dr. Reddy's and the US Department of Justice agreed to the settlement of the action without any adjudication of any issue of fact or law.

In FY2018, the company filed 19 new Abbreviated New Drug Applications (ANDAs) and one New Drug Application (NDA) with the USFDA.

As of 31 March 2018, the company had 110 generic filings pending approval from the USFDA, comprising 107 ANDAs and three NDAs filed under the 505(b)(2) route of the US Federal Food, Drug and Cosmetic Act. Of the 107 ANDAs, 63 are Para IV applications.

The company had 51 subsidiaries and two joint venture companies as on 31 March 2018. During FY2018, Dr. Reddy's Laboratories Chile SpA. (in Chile), Dr. Reddy's (WUXI) Pharmaceutical Co. Limited (in China), Dr. Reddy's Laboratories Malaysia Sdn. Bhd. (in Malaysia) and Dr. Reddy's Laboratories Taiwan Limited (in Taiwan) have become subsidiary companies. DRSS Solar Power Private Limited was closed and ceased to be a joint venture company.

In FY2019, the company filed 20 new Abbreviated New Drug Applications (ANDAs) with the USFDA. As on 31 March 2019, the company had 110 generic filings pending approval from the USFDA - comprising 107 ANDAs and three New Drug Applications (NDAs).

The company had 52 subsidiaries and two joint venture companies as on 31 March 2019. During FY2019, Dr. Reddy's Laboratories (Thailand) Limited and Dr. Reddy's Laboratories Philippines Inc. have become subsidiary companies. Pursuant to sale of all the issued and outstanding membership interests in the antibiotic manufacturing facility at Tennessee, USA, Dr. Reddy's Laboratories Tennessee, LLC ceased to be a subsidiary.

During FY2019, the company launched 15 new brands in India. The company spent towards R&D expenses during FY2019 for the amount of Rs 15,607 million, or 10.1% of revenue, versus 12.9% in FY2018.

The company had 50 subsidiaries and two joint venture companies as on 31 March 2020. During FY2020, Aurigene Pharmaceutical Services Limited was incorporated as a step-down subsidiary company. Dr. Reddy's Singapore Pte. Limited and Reddy Antilles N.V. were closed and ceased to be wholly-owned subsidiaries. Dr. Reddy's Laboratories International SA ceased to be a step-down subsidiary of the company consequent to its merger with Dr. Reddy's Laboratories SA.

During FY2020, the company launched 21 new brands in India. The company also entered the nutrition segment with the launch of our diabetes nutrition drink Celevida'. The company spent towards R&D expenses during FY2020 amounting to Rs 15,410 million, or 8.8% of revenue, versus 10.1% in FY2019.

On 10 June 2020, the company completed the acquisition of select divisions of Wockhardt Limited's branded generics business in India and the territories of Nepal, Sri Lanka, Bhutan and Maldives. The business comprises a portfolio of 62 brands in multiple therapy areas, such as respiratory, neurology, venous malformations, dennatology, gastroenterology, pain, and vaccines. This entire portfolio has been transferred to the Company, along with related sales and marketing teams, the manufacturing plant located in Baddi, Himachal Pradesh, and employees. During the quarter ended 30 September 2020, the company completed the purchase price allocation. The fair value of consideration transferred is Rs 16,115 million. The company recognised Rs 373 million, Rs 14,888 million and Rs 530 million towards property, plant and equipment, intangible assets, and goodwill, respectively. The acquisition pertains to Company's Global Generics segment.

On 22 October 2020, the Company experienced a cybersecurity incident related to ransomware. The Company could contain the incident in a timely fashion and has also ensured that all traces of the infection are completely cleaned from the network. All affected systems were restored and brought back to normalcy in the order of priority. Based on the forensic investigation, no evidence was found of any data breaches leading to personally identifiable information. Since then, the Company has also been focused on implementing significant improvements to its cyber and data security systems to safeguard from such risks in the future.

The Company continues to consider the impact of COVID-19 pandemic in assessing the recoverability of receivables, goodwill, intangible assets, and certain investments.

During December 2020, the company entered into a definitive agreement with Glenmark Phannaceuticals Ltd. to acquire, certain brands in various Emerging Market countries for a total consideration of Rs 1,516 million. The said transaction was accounted for as an acquisition of product related intangibles.

In FY 2020, Company filed 8 new Abbreviated New Drug Applications (ANDAs) with the USFDA. As on 31 March 2020, there were 99
generic filings pending approval from the USFDA, comprising 97 ANDAs and 2 New Drug Applications (NDAs).

During the year, the Company filed 20 abbreviated new drug applications (ANDAs) and 1 new drug application (NDA) in the USA. As of March 31, 2021, there were 95 generic filings awaiting approval with the US Food and Drug Administration (USFDA), comprising 92 ANDAs and 3 NDAs.

The company had 52 subsidiaries and 1 joint venture company as on March 31, 2021.

During FY 2021, Dr. Reddy's (Beijing) Pharmaceutical Company Limited in China and Dr. Reddy's Formulations Limited in India were incorporated as a step-down subsidiary company and a wholly-owned subsidiary, respectively. Pursuant to sale of the membership interests in DRANU, LLC, it ceased to be a joint venture during the year. Further, the company sold its Contract Development and Manufacturing Organization (CDMO) division of Custom Pharmaceutical Services (CPS) business to Aurigene Pharmaceutical Services Limited (APSL), a wholly-owned subsidiary, on slump sale basis, for a consideration of Rs. 5,434.5 million.

During year 2022, Company filed 7 Abbreviated New Drug Applications (ANDAs) in the USA. As of March 31, 2022, there were 90 generic filings awaiting approval with the US Food and Drug Administration (USFDA), comprising 87 ANDAs and 3 NDAs.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad Bench, vide order dated April 5, 2022, has approved the Scheme of Amalgamation and Arrangement for the merger of Dr. Reddy's Holdings Limited (the DRHL/ Amalgamating Company) with the Company, filed by both companies with the Registrar of Companies, Hyderabad, on April 8, 2022. Therefore, the merger became effective on April 8, 2022 with Appointed date of the Scheme, April 1, 2019.

The Company has 42 overseas subsidiary companies (including step-down subsidiaries), 9 subsidiary companies in India and 1 joint venture Company as on March 31, 2022.

Dr. Reddy's (WUXI) Pharmaceutical Co. Limited in China ceased to be a step-down subsidiary of the Company with effect from December 13, 2021, consequent to its liquidation. Aurigene Discovery Technologies Inc. in USA, ceased to be a step-down subsidiary of the Company with effect from March 23, 2022, consequent to its liquidation. Further, the Company acquired Nimbus Health GmbH (Nimbus) as a step-down subsidiary, on February 24, 2022.

During the year 2022-23, Dr. Reddy's Holdings Limited (the DRHL/ Amalgamating Company) got merged with Dr Reddy's Laboratories Ltd. (the Amalgamated Company) through the Scheme of Amalgamation and hence, the merger became effective on April 8, 2022.

Consequent to the merger with Dr. Reddy's Laboratories LLC, Russia, DRS LLC in Russia ceased to be a step down subsidiary of the Company with effect from July 1, 2022. Dr. Reddy's Laboratories B.V. in Netherlands, has ceased to be a step-down subsidiary of the Company with effect from January 25, 2023.

During the year 2023, the Company launched the generic version of Lenalidomide Capsules, a cancer drug used to treat myeloma in the United States; launched Sorafenib tablets, a drug used to treat a type of liver cancer called hepatocellular carcinoma; launched Timolol gel, an ophthalmic gel forming solution used to treat glaucoma.

In 2024, Company diversified the business to patients women's healthcare in the US Consumer Healthcare and its first ever biosimilar in the UK, and vaccines in India. It took step in the area of digital therapeutics, with the launch of the drug-free migraine management device Nerivior, and a digital integrated care plan to manage Irritable Bowel Syndrome (IBS). The Company formed a joint venture with Nestlé India to introduce health science nutraceutical products to consumers across India and other agreed territories. It entered the UK consumer health market with the launch of the OTC allergy medication Histallay.

Parent organization Dr. Reddy's
NSE symbol DRREDDY
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Dr Reddys Laboratories Ltd?

Answer Field

The share price of Dr Reddys Laboratories Ltd for NSE is ₹ 1183.9 and for BSE is ₹ 1183.

What is the Market Cap of Dr Reddys Laboratories Ltd?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE is ₹ 1,97,49.62 Cr. and for BSE is ₹ 1,97,34.60 Cr. as of now.

What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?

Answer Field

The 52 Week High and Low of Dr Reddys Laboratories Ltd for NSE is ₹ 1421.49 and ₹ 1020.00 and for BSE is ₹ 1420.20 and ₹ 1025.90.

How to Buy Dr Reddys Laboratories Ltd share?

Answer Field

You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Dr Reddys Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -4.59%.

What is the Current Share Price of Dr Reddys Laboratories Ltd?

Answer Field

Dr Reddys Laboratories Ltd share price is for NSE ₹ 1183.9 & for BSE ₹ 1183 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Dr Reddys Laboratories Ltd Share?

Answer Field

The market cap of Dr Reddys Laboratories Ltd for NSE ₹ 1,97,49.62 & for BSE ₹ 1,97,34.60 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Dr Reddys Laboratories Ltd share is 19.04.

What is the PB ratio of Dr Reddys Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Dr Reddys Laboratories Ltd share is 322.46.

How to Buy Dr Reddys Laboratories Ltd Share?

Answer Field

You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Dr Reddys Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Dr Reddys Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Dr Reddys Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Dr Reddy's Laboratories Ltd?

Answer Field

Erez Israeli has held the position of CEO at Dr Reddy's Laboratories Ltd since 1 Aug 2019. He leads the company in advancing pharmaceutical innovations and global market reach, focusing on sustainable growth and maintaining Dr Reddy's competitive position within the industry.

When was Dr Reddy's Laboratories Ltd established?

Answer Field

Dr Reddy's Laboratories Ltd was founded in 1984 in Hyderabad, India, by Dr. Anji Reddy. The company began by manufacturing Active Pharmaceutical Ingredients (APIs) and quickly expanded to become one of India’s leading pharmaceutical companies with a significant global presence.

What factors influence the Dr Reddy Share Price?

Answer Field

Dr Reddy share price is influenced by multiple factors, including financial performance, revenue growth, and profitability. Sector trends, global market conditions, regulatory changes, and investor sentiment also impact share value, shaping the overall market perception of Dr Reddy's potential for future growth.

Is Dr Reddy's Laboratories Ltd debt free?

Answer Field

Dr Reddy's Laboratories Ltd is not entirely debt-free; however, the company maintains a balanced debt-to-equity ratio, ensuring debt levels remain manageable. This strategic financial management allows Dr Reddy's to invest in growth opportunities while maintaining financial stability and supporting long-term shareholder value.

What is the CAGR of Dr Reddy Share?

Answer Field

The Compound Annual Growth Rate (CAGR) for Dr Reddy share is 6% over 10 years, 19% over 5 years, 10% over 3 years, and 19% over the last year. These figures reflect the company’s growth trajectory and its consistent performance in the pharmaceutical sector.

How has the Dr Reddy Share Price performed over the past year?

Answer Field

Over the past year, Dr Reddy share price has demonstrated a positive performance, showing a 19% growth in CAGR. This growth highlights investor confidence and reflects the company’s strong market position, profitability, and financial resilience within the highly competitive pharmaceutical industry.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|